Notably, Wagle et al. reported the emergence of an mTOR F2108L mutation in patient with anaplastic thyroid cancer bearing an inactivating TSC2 mutation, after 18 months of treatment on everolimus. Here, TSC2 is linked to thyroid gland undifferentiated (anaplastic) carcinoma.